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Abstract
Multiple Sclerosis (MS) is a chronic inflammatory neurological disease of the Central Nervous System (CNS),
characterized by demyelination and activation of microglia. Mitochondrial mutations and dysfunctions in microglial
cells are thought to contribute to the detrimental effects of neuroinflammation seen in MS. The Somatic Nuclear
Transfer (SCNT) technology offers a more practical mode of therapy in MS, this method would attempt to dilute
and/or progressively replace the mutated and activated microglia with cloned Olfactory Ensheathing Cells (OEC)
with remyelinating and scavenging properties which would attempt to limit the progression of MS. Applying SCNTderived Embryonic Stem (ES) cells based therapy by cloning Olfactory Ensheathing Cells (OEC), engineered with
an autologous nuclear component of the recipient OEC with a healthy donor oocyte. The inner cell mass of the
subsequently developed blastocyst would be the source to generate the radial microglia to be used for cell therapy
in MS. The novel proposed transcribrial route device offers a painless mode of cell transplantation to the brain. This
mode of generating cloned glia and its transplantation to the brain is expected to replace the mutated and activated
microglia of the patients with MS and use the regenerative and remyelinating and scavenging properties of the OEC’s,
as has been seen in clinical trials in patients with spinal cord injuries. The use of SCNT to develop isogenic ES cellbased therapies for the prevention and treatment of MS associated with mtDNA mutations may open a new avenue
of designer’s targeted cell therapy unique for the patients with MS. The proposed “transcribrial device” to access the
brain can be an advantageous route of delivery of cloned cells to the brain.
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Current Scenarios in the Drug Management of Multiple
Sclerosis

Introduction

As a result of the past 20 years of research done for treatment
of MS, various forms of auto injectable interferon beta (IFN b) and
Glatiramer acetate (GA) got into the market with GA 40 mg given
subcutaneously reduced the relapse rate at 1 year [9] and became
widely used as first line disease treatments. Natalizumab, and to a much
lesser extent Mitoxantrone, are second-line intravenously infused
treatments. With teriflunomide in patients with relapsing MS study
showed teriflunomide’s clinical efficacy in reducing the relapse rate
and neurological deficits in MS over a period of 2 years [10]. Several
phase III studies in relapsing MS are ongoing for second-generation
sphingosine-1-phosphate receptor 1 immunomodulators which show
promise in reducing some of the side effects associated with such an
agent like bradycardia, abnormal hepatic enzyme elevations, and lung
fibrosis [8]. Vitamin D deficiency has been recently identified as a
risk factor and its potential in the possible disease modifying role and
awaits clinical trials in the relapsing MS [11].

Stem cell therapy; Regenerative medicine; SCNT

Multiple sclerosis (MS) is a chronic inflammatory neurological
disease of the central nervous system; characterized by demyelination,
neurodegeneration and astroglial proliferation [1], with complex
genetic factors exerting a profound influence [2]. Despite major
advances in the current understanding of the pathogenesis of MS, the
inflammatory cascade involved in MS remains unknown; although there
is considerable evidence implicating the involvement of mitochondria
DNA mutations involved in axonal and glial injury mechanisms [35]. Mitochondrial dysfunction in microglial cells has been observed in
several animal models of neurodegeneration and aging, in this regard
the mitochondrial DNA damage in particular is most pronounced
within microglial cells, especially compared to neurons [6]. There is
currently no treatment for the loss of neuronal function after damage
to the nervous system, multiple attempts at nerve re-growth across
the peripheral nervous system (PNS) and (CNS) transition have not
been successful [7]. Injuries and neurodegenerative (ND) diseases of
the central nervous system (CNS), like MS are unique in that they
almost always get repaired by gliosis leading to loss of neurological
function and resultant neurological deficits in the affected individual.
Widespread microglial activation is a histopathological hallmark of
progressive MS and inhibition of this aspect of innate immunity could
potentially have beneficial effects on both progressive and relapsing
forms of MS [8]. Majority of ND, including (MS) is characterized by
activation of microglia and mitochondrial dysfunction in microglial
cells are thought to contribute to the harmful effects neuroinflammation
seen in these diseases [6]. One of the most distressing aspects of MS
treatment is the failure of development of disease-modifying therapies
that slow disability in progressive forms of MS. At present, none of the
drugs do attempt to reduce the inflammatory process and target either
the primary progressive or secondary progressive MS [8]. Very trivial
studies in animal models have come up in the field of cell therapy as a
treatment modality for this demyelinating disease.
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Current Status of Stem Cell Therapy in Multiple Sclerosis
In humans, neurogenesis largely ceases during adulthood, but in
two areas of the brain, the hippocampus and olfactory bulb, there is
strong evidence of regeneration of substantial numbers of new neurons

*Corresponding author: Abdul Mannan Baig, Department of Biological and
Biomedical Sciences, Aga Khan University, Stadium Road, Karachi, Pakistan, Tel:
92-(0)21-3486-4435; Fax: 92-(0)21-3493-4294; E-mail: abdul.mannan@aku.edu
Received July 10, 2014; Accepted December 06, 2014; Published December
08, 2014
Citation: Baig AM (2014) Cloned Microglias with Novel Delivery System in Multiple
Sclerosis. J Stem Cell Res Ther 4: 252. doi:10.4172/2157-7633.1000252
Copyright: © 2014 Baig AM. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and
source are credited.

Volume 4 • Issue 11 • 1000252

Citation: Baig AM (2014) Cloned Microglias with Novel Delivery System in Multiple Sclerosis. J Stem Cell Res Ther 4: 252. doi:10.4172/21577633.1000252

Page 2 of 4
[12]. Studies done in detail on the use of (ESCs) in MS have revealed
that the actual limitation is the preparation of sufficient human
oligodendrocytes precursor cells in getting tissue-specific progenitor
cells from human embryonic stem cells (ESCs) and the dangers that
there are always risk of tumorogenesis in neural cells derived from
ESCs, limiting the potentialities of science and therapy in such studies
[13]. Another shortcoming of the autologous MSC and induced
pluripotent stem cells (iPS), transplantation in the treatment of MS
is that of carrying the inherited (mtDNA) mutation to the CNS. For
MSC there is lingering doubt whether the MSC derived neurons are
functional [14], and as similar fate could be expected if it ends up
differentiating into a glia.

Recommendation for a Novel Cell Therapy in Multiple
Sclerosis
From extensive reviews on the cell therapy methodologies it can
be computed that partial successes or disappointments encountered
in treating MS with autologous embryonic stem cell transplants have
occurred due to immune rejection and/or persistence of inherited or
acquired mutated mitochondrial DNA in the glial cells in the case of
autologous iPS transplants. Although transplantation of Mesenchymal
Stem Cell (MSC), or induced pluripotent stem (iPS) cells generated
from autologous somatic OECs and reprogrammed into ES-like cells
may provide an additional source of autologous stem cells for treating
MS, both would be of no potential benefit as would continue to harbour
the same mitochondrial mutations (mtDNA) as possessed by glia in
CNS [15]. The field of mitochondrial-targeted therapeutics is one that
is growing fast and is of great importance and an increasing evidence
points towards mutation leading to altered mitochondrial trafficking

and fusion-fission dynamics in several ND diseases including MS [16].
MS can be targeted for slowing down the progression, prevention of
onset and possible treatment by perhaps by the proposed genetically
modified glial cells cloned by somatic Nucleus Transfer (NT) of
Olfactory ensheathing cells to a healthy donor oocyte devoid of
mtDNA mutations. OECs normally perform regenerative, scavenging
and innate immune functions in the olfactory region and have been
investigated thoroughly in related to spinal cord injuries, amyotrophic
lateral sclerosis and other ND diseases where research suggests that
these cells possess a unique ability to remyelinate injured neurons [17].
A new strategy for isolating oligodendrocyte progenitor cells of the
human brain may advance the goal of therapeutic remyelination [18].
Here we propose glia cloned with an autologous nuclear component
of the recipient’s OEC’s, union by combination of whole somatic
OECs with a healthy oocyte cytosol [15] (Figure 1), offers an alternate
speculative likelihood of producing NT-derived ES cells in which
mutated mtDNA is substantially diluted/destroyed by the mtDNA of
oocyte as it does to the mitochondrial DNA of the spermatozoa, shortly
after fertilization. The resulting inner cell mass from the blastocyst
stage of development would become a source of induced pluripotent
stem cells that would differentiate into a radial glia like OEC’s with the
inherent properties of axonal and myelin generation and scavenging
functions. Xenotranplantation of myelin-forming OEC’s from pigs
genetically altered to reduce the hyperacute response in humans are
able to induce elongative axonal regeneration and remyelination and
restore impulse conduction across the transected spinal cord [19]. The
transplantation of the proposed cells followed by the self-renewal of
this ESC at sites of demyelination would attempt to repair the gliosis
and dilute the activated microglia population that is the leading cause
of defects seen in MS.

Figure 1: Olfactory Mucosa (OM) and Olfactory Bulb (OB) contain Olfactory Ensheathing Cells (OECs). The single Somatic Nuclear Transfer (SCNT) to an enucleated
Oocyte would develop into a blastocyst. The inner cell mass differentiating into radial microglia could be used for transplantation into the central nervous system in
Multiple Sclerosis.
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After being reported that transplantation of heterologous fetal OECs
into the frontal lobes it has been seen to slow down the rate of clinical
progression in ALS patients, the subsequent neuropathologic analysis
did not support a therapeutic efficacy for ALS patients even after OEC
transplantation via the ventricles, although transplantation of OECs
engineered to produce neurotrophins might be helpful to improve the
condition in ALS [17]. Culturing and transplanting this cloned glia that
expresses identical HLA antigens would not evoke an autoimmune
rejection while the mitochondria’s of oocyte of a healthy donor
would possibly dilute the activated microglia slow down the ongoing
neuronal degeneration [6,15,16]. The additional rewarding benefit of
such transplantation would be that the regenerative and scavenging
potentials of OECs in contrast to the over reactive microglia present
in the CNS of the MS patients, would help recover the damage already
caused by the degenerative process, a feature missing in mesenchymal
stem cells (MSC) and iPS. The use of the NT to develop isogenic ES
cell-based therapies for the prevention and treatment of MS associated
with mtDNA mutations may open a new avenue of designer’s targeted
cell therapy unique for the patients with MS.

Weighing the Benefits Ahead of Transplantations
The nuclear profiling of the cloned glia by microarray for differential
expression of mtDNA and nuclear DNA of these engineered cells
prior to transplant would clearly highlight the benefits of the planned
transplantation. A similar gene profiling of the patient's glial cells
would help understand the differences in their epigenetic expression
and the gains of the procedure in the ongoing MS in the patients. Once
evaluated and approved for transplant, these cloned cells like their
parent OEC’s can be labelled and tracked by a magnetic resonance
imaging (MRI) device when being dispersed in the CNS. A recent study
has made use of a novel type of Micron-sized Particles of Iron Oxide
(MPIO) to label and track these transport-mediated cells via MRI [20].

Novel Delivery via transcribrial route device
The advantage of transplantation techniques done in past via
intrathecal, intraventricular, intra-parenchyma and several other
routes can be considered for the aforementioned cloned glial cells.
Methods of cells being delivered to CNS through an intranasal
route has been reported in the past. The nasal route has therapeutic
effects that appear to be equivalent to those induced by intravenous
route adult neural stem cells (NSCs) and lead to protection from
CNS inflammation and the promotion of remyelination and neural
repair. Such an effective alternative route of administration could
significantly improve the efficacy of NSC-based therapy in MS [21].
There is potential of this intranasal route principally for the therapy of
neurodegenerative disorders, this delivery method provides the option
of chronic treatment which may enhance the number of delivered cells
in order to achieve therapeutic benefit [22].
We have recently proposed a “transcribrial route device” that is
composed of three connected components [23] to access the brain across
the criribriform plate of the ethimoid bone. This can be of advantage
because of being painless and the trimmed ball-valve terminal could
prevent any regurgitation back into the delivery system. A local
anaesthetic application prior to the cell therapy could minimize the
reflex sneezing that is expected on insertion of the nasal components.
Unlike other routes this route would clearly avoid the risks of escape of
the cells into the lungs and various neurological complications of other
cell therapy delivery systems.
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